WILLIAM H. MILLER, PH.D.

Collegeville, PA 19426
+1 (610) 724-1618
whmiller@medchem-innovations.com
https://medchem-innovations.com
www.linkedin.com/in/william-h-miller

MEDICINAL CHEMISTRY AND DRUG DISCOVERY PROFESSIONAL

Accomplished scientific leader with extensive drug discovery experience at Fortune 500 pharmaceutical companies. Expertise in medicinal and synthetic organic chemistry, preclinical drug discovery research, and implementing medicinal chemistry and drug discovery strategies to accelerate the design, synthesis, evaluation and progression of high-quality drug candidates. Established track record for successfully advancing initial hits to viable development candidates, and for identifying creative solutions to complex drug discovery challenges. Proficient in R&D leadership, and in building and managing successful, high-performing teams. Significant US and global CRO outsourcing and management experience.

- Contributed to the identification of 18 development candidates, including the late-stage clinical assets Daprodustat, Gepotidacin, Afabicin and Lotrafiban.
- Inventor on 65+ issued US patents and authorship on 40+ journal publications.

EXPERTISE

- Medicinal and synthetic organic chemistry, and preclinical drug discovery research.
- Hit identification, advancing initial hits to sustainable leads, lead optimization, analog design, synthetic route design and optimization, structure-based drug design, fragment-based drug design, molecular modeling (MOE), DMPK, due diligence evaluations, and patent preparation.
- Scientific, managerial, and strategic leadership of multi-disciplinary teams, and teams of up to 26 internal chemists or 40+ external CRO scientists.
- Collaborating across multiple disciplines, including biology, biochemistry, medicinal chemistry, development chemistry, DMPK, safety assessment, and CMC, to deliver development candidates.
- Externalization / outsourcing of R&D activities, including medicinal chemistry, scale-up chemistry, biology and DMPK, at US and international (China and India) contract research organizations (CROs).
- Therapeutic areas: antibacterials, cardiovascular, dermatology, inflammation, neuroscience (pain), oncology, ophthalmology, osteoporosis, and supportive care.
- Target classes: enzymes (including bacterial enzymes, epigenetic enzymes, kinases, prolyl hydroxylase, sirtuins, thrombin), receptors (integrins), and ion channels.
- Oral, intravenous and topical routes of administration.

EXPERIENCE

MEDCHEM INNOVATIONS, LLC, Collegeville, PA **05/2019-Present**
Principal Consultant

Partner with clients in need of medicinal chemistry support, to deliver cost-effective drug discovery solutions from hit identification through lead optimization to the identification and progression of high-quality development candidates.

GLAXOSMITHKLINE (SMITHKLINE BEECHAM), Collegeville, PA; King of Prussia, PA **12/1991-05/2019**
Senior Director, Medicinal Chemistry (04/2013-05/2019)

Senior chemistry research director responsible for providing leadership and guidance for medicinal chemistry teams, the medicinal chemistry community, program teams, Discovery Performance Units (DPUs), and the overall business.

- Member of the leadership team that planned, built, and led the Sirtuin Discovery Performance Unit (DPU), following the closure of Sirtris in Cambridge, MA.
- Contributed to the identification of developable SIRT1 activators, including an orally active development candidate, even though the target is a flat, lipophilic surface.
- Member of the leadership team that re-established the Neuroexcitation DPU, following the closure of this group at another GSK site.
- Contributed to the identification of novel inhibitors of voltage-gated sodium channels for the treatment of pain.
- Chemistry adviser for GSK Dermatology, assisting with development of a standard critical path for topical drug discovery, and identification of molecules with suitable properties for topical delivery.
- Early Development Leader for a GSK asset, with responsibility for leading a multidisciplinary development team through enabling, post-candidate-selection studies to support Phase I clinical investigation.

Director, Medicinal Chemistry (09/2002-04/2013)

Chemistry research director responsible for providing leadership and guidance for medicinal chemistry teams, the medicinal chemistry community, program teams, DPUs, and the overall business.

- Member of the leadership team that planned, built, and led the GSK Cancer Epigenetics DPU, an industry-leading oncology epigenetics drug discovery group.
- Contributed to the identification of multiple, epigenetics-targeted development candidates from internal efforts and external collaborations. Several of these agents have entered clinical trials.
- Contributed to the identification of the HIF prolyl hydroxylase inhibitor Daprodustat, currently in Phase III trials for the treatment of anemia.
- Led the US chemistry effort on the transnational (UK/US) BTI Program. The program identified the antibacterial agent Gepotidacin, currently entering Phase III trials.
- Contributed to the identification of an antibacterial peptide deformylase inhibitor that entered Phase II trials.
- Contributed to the identification of quality inhibitors/development candidates targeting various oncology kinases (AKT, Aurora-B, FAK, PAK1, PDK1).
- MedChem representative on teams that designed/built new chemistry lab space.
- Established a stringent review process for compounds advancing into toxicology studies.
- Developed a new, standardized/streamlined process for obtaining small molecule X-ray crystal structures from external sources.

Manager (GSK)/Assistant Director (SB), Medicinal Chemistry (06/1998-09/2002)

Chemistry research manager responsible for providing leadership and guidance for multiple medicinal chemistry teams and multiple program teams.

- Co-leader/chemistry team leader of the Vitronectin Program, which advanced three compounds into development (two of which entered Phase I trials).
- Co-leader/chemistry team leader of the FabI Program, which identified novel, potent FabI-directed antibacterial agents. A molecule from this effort (Afabicin) is in Phase II trials.
- Built and led the Upper Providence MedChem Safety Program, which received company-wide recognitions for best safety practices and achieved 50/50 on safety audits.
- Performance review: "…substantial intellectual contributions to the efforts…extraordinary creativity, efficiency and productivity".

Associate Senior Investigator, then Senior Investigator, Medicinal Chemistry (12/1991-06/1998)

Initially I was a lab chemist designing/synthesizing small molecule integrin antagonists, and advanced to program co-leader/chemistry team leader. Led chemistry efforts and collaborated with biology co-leaders to oversee the overall drug discovery efforts of program teams.

- Instrumental in the identification of potent, selective integrin $\alpha v\beta 3/\alpha v\beta 5$ antagonists with high oral bioavailability, solving a long-standing challenge.
- Contributed significantly to the investigation of benzodiazepine-based screening leads and the identification/optimization of three series of highly potent, orally active $\alpha v\beta 3/\alpha v\beta 5$ antagonists (benzazepines, dibenzocycloheptenes, and phenylbutyrates).
- Investigated small molecule antagonists of integrin $\alpha IIb\beta 3$ as a lab chemist in the Fibrinogen Program, which identified Lotrafiban (terminated in Phase III trials).
- Coordinated and contributed significantly to the successful development of the first enantioselective synthesis of Lotrafiban.
- Collaborated with attorneys and other chemists to design and implement a new priority patent filing process.

DUPONT MERCK PHARMACEUTICAL COMPANY, Wilmington, DE **09/1989-12/1991**
Research Scientist, then Senior Research Scientist, Medicinal Chemistry

Laboratory chemist involved in the design and synthesis of target molecules.

- Investigated inhibitors of IL-1 biosynthesis, and cartilage degradation, for treatment of arthritis, and boropeptide-based thrombin inhibitors for treatment of clotting disorders.

EDUCATION

HARVARD UNIVERSITY | **NIH Postdoctoral Fellow – Synthetic Organic Chemistry**
Research Adviser: Professor Yoshito Kishi
Research: Conformational analysis of C- and O-disaccharides
Synthetic studies towards the taxane diterpenes

YALE UNIVERSITY | **Ph.D. – Synthetic Organic Chemistry**
Research Adviser: Professor Samuel J. Danishefsky
Dissertation: An Approach to the Total Synthesis of Anguidine

UNIVERSITY OF CONNECTICUT | **B.S. in Chemistry with Honors – Graduated *Magna Cum Laude***
Research Adviser: Professor Gary A. Epling
Honors Thesis: Photochemistry from Upper Excited States

AFFILIATIONS

American Chemical Society, Organic and Medicinal Chemistry Divisions of the American Chemical Society, Philadelphia Organic Chemist's Club

TECHNOLOGY

MOE, ScFinder, Reaxys, Microsoft Office Suite (Word, Excel, PowerPoint), ChemDraw.

REFERENCES

James L. Ellis, Ph.D. CSO Nocion Therapeutics, Inc. jim@nociontx.com (617) 230-4817 (mobile)	Zheng Li, Ph.D. VP, Head of Neuroexcitation DPU GlaxoSmithKline zheng.n.li@gsk.com (734) 730-2505 (mobile)
Karen A. Evans, Ph.D. Manager, Medicinal Chemistry GlaxoSmithKline karen.a.evans@gsk.com (610) 917-7764 (work)	Allen I. Oliff, MD SVP, Senior Discovery Consultant GlaxoSmithKline allen.i.oliff@gsk.com (484) 767-2784 (mobile)
Ryan M. Fox Operations Director GlaxoSmithKline ryan.m.fox@gsk.com (610) 220-6394 (mobile)	David Rubenstein, MD, Ph.D. CSO Dermavant Sciences, Inc. david.rubenstein@dermavant.com (919) 414-6127 (mobile)
Erding Hu, Ph.D. Exploratory Biology Director GlaxoSmithKline erding.hu@gsk.com (610) 324-2258 (mobile)	Peter Tummino, Ph.D. CSO Nimbus Therapeutics peter.tummino@nimbustx.com (610) 291-6238 (mobile)
Richard M. Keenan, Ph.D. Principal Consultant RMK Drug Discovery Consulting, LLC rickkeenan@gmail.com (610) 585-1183 (mobile)	

ISSUED US PATENTS

1. Miller, W. H. H-[1,2]Benzisothiazolo[2,3a]quinoline-5-ones and analogs as anti-inflammatory agents. US 5,225,418, issued 06 July 1993.
2. Miller, W. H. 5H-[1,2]Benzisothiazolo[2,3a]quinoline-5-ones and analogs as anti-inflammatory agents. US 5,393,756, issued 28 February 1995.
3. Amparo, E. C.; Miller, W. H.; Pacofsky, G. J.; Wityak, J.; Weber, P. C.; Duncia, J. J. V.; Santella III, J. B. Boronic acid and ester inhibitors of thrombin. US 5,563,127, issued 08 October 1996.
4. Amparo, E. C.; Miller, W. H.; Pacofsky, G. J.; Wityak, J.; Weber, P. C.; Duncia, J. J. V.; Santella III, J. B. Boronic acid and ester inhibitors of thrombin. US 5,698,538, issued 16 December 1997.
5. Keenan, R. M.; Miller, W. H. Substituted benzimidazoles which inhibit platelet aggregation. US 5,741,804, issued 21 April 1998.
6. Ali, F. E.; Bondinell, W. E.; Huffman, W. F.; Lago, M. A.; Keenan, R. M.; Kwon, C.; Miller, W. H.; Nguyen, T. T.; Takata, D. T. Benzimidazoles/imidazoles linked to a fibrinogen receptor antagonist template having vitronectin receptor antagonist activity. US 5,977,101, issued 02 November 1999.
7. Bondinell, W. E.; Miller, W. H. Integrin receptor antagonists. US 6,008,213, issued 28 December 1999.
8. Kwon, C.; Miller, W. H. Bicyclic compounds. US 6,008,214, issued 28 December 1999.
9. Galemmo, R. A., Jr.; Abelman, M. M.; Amparo, E. C.; Fevig, J. M.; Knabb, R. M.; Miller, W. H.; Pacofsky, G. J; Weber, P. C. Cacciola, J. Electrophilic peptide analogs as inhibitors of trypsin-like enzymes. US 6,060,462, issued 09 May 2000.
10. Ali, F. E.; Bondinell, W. E.; Calvo, R. R.; Ku, T. W.; Miller, W. H.; Samanen, J.; Venslavsky, J. W.; Yellin, T. O. Fibrinogen receptor antagonists. US 6,069,143, issued 30 May 2000.
11. Miller, W. H.; Bondinell, W. E.; Ku, T. W. Vitronectin receptor antagonists. US 6,069,158, issued 30 May 2000.
12. Ali, F. E.; Bondinell, W. E.; Keenan, R. M.; Ku, T. W.; Miller, W. H.; Samanen, J. M. Vitronectin receptor antagonists. US 6,159,964, issued 12 December 2000.
13. Miller, W. H.; Bondinell, W. E.; Ku, T. W. Vitronectin receptor antagonists. US 6,191,304, issued 20 February 2001.
14. Cousins, R. D.; Keenan, R. M.; Kwon, C.; Miller, W. H.; Uzinskas, I. N. Vitronectin receptor antagonists. US 6,458,784, issued 01 October 2002.
15. Manley, P. J.; Miller, W. H. Vitronectin receptor antagonists. US 6,458,814, issued 01 October 2002.
16. Miller, W. H.; Manley, P. J. Vitronectin receptor antagonist. US 6,495,560, issued 17 December 2002.
17. Miller, W. H.; Newlander, K. A.; Seefeld, M. A. FabI inhibitors. US 6,503,903, issued 07 January 2003.
18. Miller, W. H.; Newlander, K. A.; Seefeld, M. A. Antibacterial compounds. US 6,573,272, issued 03 June 2003.
19. Bondinell, W. E.; Miller, W. H.; Heerding, D.; Samanen, J. M. Vitronectin receptor antagonists. US 6,576,643, issued 10 June 2003.
20. Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N. FabI inhibitors. US 6,730,684, issued 04 May 2004.
21. Miller, W. H.; Newlander, K. A.; Seefeld, M. A. FabI inhibitors. US 6,762,201, issued 13 July 2004.
22. Miller, W. H.; Newlander, K. A.; Seefeld, M. A. FabI inhibitors. US 6,765,005, issued 20 July 2004.

23. Callahan, J. F.; Cousins, R. D.; Keenan, R. M.; Kwon, C.; Miller, W. H.; Uzinskas, I. N. Vitronectin receptor antagonists. US 6,825,188, issued 30 November 2004.

24. Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N.; DeWolf, W. E., Jr.; Jakas, D. R. FabI inhibitors. US 6,846,819, issued 25 January 2005.

25. Manley, P. J.; Miller, W. H.; Uzinskas, I. N. Vitronectin receptor antagonists. US 6,881,736, issued 19 April 2005.

26. Miller, W. H.; Newlander, K. A.; Seefeld, M. A. Antibacterial compounds. US 6,964,970, issued 15 November 2005.

27. Burgess, W. J.; Jakas, D. R.; Huffman, W. F.; Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N. FabI inhibitors. US 7,049,310, issued 23 May 2006.

28. Daines, R. A.; Miller, W. H.; Pearson, N. D.; Pendrak, I.; Seefeld, M. A. Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them. US 7,109,213, issued 19 September 2006.

29. Davies, D. T.; Jones, G. E.; Markwell, R. E.; Miller, W.; Pearson, N. D. Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents. US 7,205,408, issued 17 April 2007.

30. Axten, J. M.; Miller, W. H.; Seefeld, M. A.; Antibacterial agents. US 7,232,832, issued 19 June 2007.

31. Burgess, W. J.; Jakas, D. R.; Huffman, W. F.; Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N. FabI inhibitors. US 7,250,424, issued 31 July 2007.

32. Daines, R. A.; Miller, W. H.; Pearson, N. D.; Pendrak, I.; Seefeld, M. A. Aminopiperidine derivatives. US 7,312,212, issued 25 December 2007.

33. Axten, J. M.; Daines, R. A.; Davies, D. T.; Gallagher, T. F.; Jones, G. E.; Miller, W. H.; Pearson, N. D.; Pendrak, I. Compounds. US 7,498,326, issued 03 March 2009.

34. Miller, W. H.; Rouse, M. R.; Seefeld, M. A. Antibacterial agents. US 7,511,035, issued 31 March 2009.

35. Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N.; DeWolf, W. E., Jr.; Jakas, D. R. FabI inhibitors. US 7,524,843, issued 28 April 2009.

36. Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N.; DeWolf, W. E., Jr.; Jakas, D. R. FabI inhibitors. US 7,557,125, issued 07 July 2009.

37. Miller, W. H.; Rouse, M. R.; Seefeld, M. A. Antibacterial agents. US 7,592,334, issued 22 September 2009.

38. Miller, W. H.; Seefeld, M. A. Antibacterial agents. US 7,605,169, issued 20 October 2009.

39. Duffy, K. J.; Miller, W. H.; Myers, A. K.; Shaw, A. N.; Zimmerman, M. N. N-substituted glycine derivatives: hydroxylase inhibitors. US 7,608,621, issued 27 October 2009, and RE 44,613 (reissue of US 7,608,621), issued 26 November 2013.

40. Axten, J. M.; Gallagher, T. F.; Miller, W. H.; Seefeld, M. A.; Antibacterial agents. US 7,618,959, issued 17 November 2009.

41. Axten, J. M.; Daines, R. A.; Davies, D. T.; Gallagher, T. F.; Jones, G. E.; Miller, W. H.; Pearson, N. D.; Pendrak, I. Antibacterial compounds. US 7,622,481, issued 24 November 2009.

42. Miller, W. H.; Rouse, M. R.; Seefeld, M. A. Antibacterial agents. US 7,648,980, issued 19 January 2010.

43. Miller, W. H.; Axten, J. A.; Seefeld, M. A. Antibacterial agents. US 7,648,984, issued 19 January 2010.

44. Miller, W. H.; Seefeld, M. A. Antibacterial agents. US 7,655,648, issued 02 February 2010.

45. Miller, W. H.; Pendrak, I.; Seefeld, M. A. Antibacterial agents. US 7,691,850, issued 06 April 2010.
46. Miller, W. H.; Rouse, M. R.; Seefeld, M. A. Antibacterial agents. US 7,709,472, issued 04 May 2010.
47. Miller, W. H.; Price, A. T. Antibacterial agents. US 7,709,496, issued 04 May 2010.
48. Burgess, W. J.; Jakas, D. R.; Huffman, W. F.; Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N. FabI inhibitors. US 7,741,339, issued 22 June 2010.
49. Miller, W. H.; Rouse, M. R.; Seefeld, M. A. Antibacterial agents. US 7,759,340, issued 20 July 2010.
50. Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N.; DeWolf, W. E., Jr.; Jakas, D. R. FabI inhibitors. US 7,790,716, issued 07 September 2010.
51. Burgess, W. J.; Jakas, D. R.; Huffman, W. F.; Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N. FabI inhibitors. US 8,153,652, issued 10 April 2012.
52. Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N.; DeWolf, W. E., Jr.; Jakas, D. R. FabI inhibitors. US 8,173,646, issued 08 May 2012.
53. Miller, W. H.; Tian, X.; Verma, S. K. Indoles. US 8,536,179, issued 17 September 2013.
54. Burgess, J. L.; Johnson, N.; Knight, S. D.; LaFrance, L.; Miller, W. H.; Newlander, K.; Romeril, S.; Rouse, M. B.; Tian, X.; Verma, S. K.; Suarez, D. Azaindazoles. US 8,637,509, issued 28 January 2014.
55. Axten, J. M.; Blackledge Jr., C. W.; Brady, G. P.; Feng, Y.; Grant, S. W.; Medina, J. R.; Miller, W. H.; Romeril, S. P. Chemical compounds. US 8,697,685, issued 15 April 2014.
56. Knight, S. D.; Miller, W. H.; Newlander, K. A.; Verma, S. K. Indoles. US 8,765,792, issued 01 July 2014.
57. Duquenne, C.; Johnson, N.; Knight, S. D.; LaFrance, L.; Miller, W. H.; Newlander, K.; Romeril, S.; Rouse, M. B.; Tian, X.; Verma, S. K. Indazoles. US 8,846,935, issued 30 September 2014.
58. Brackley III, J.; Burgess, J. L.; Grant, S.; Johnson, N.; Knight, S. D.; LaFrance, L.; Miller, W. H.; Newlander, K.; Romeril, S.; Rouse, M. B.; Tian, X.; Verma, S. K. Indoles. US 8,975,291, issued 10 March 2015.
59. Duquenne, C.; Johnson, N.; Knight, S. D.; LaFrance, L.; Miller, W. H.; Newlander, K.; Romeril, S.; Rouse, M. B.; Tian, X.; Verma, S. K. Indazoles. US 9,018,382, issued 28 April 2015.
60. Burgess, J. L.; Johnson, N. W.; Knight, S. D.; LaFrance III, L. V.; Miller, W. H.; Newlander, K. A.; Romeril, S. P.; Rouse, M. B.; Suarez, D.; Tian, X.; Verma, S. K. Azaindazoles. US 9,073,924, issued 07 July 2015.
61. Miller, W. H.; Tian, X.; Verma, S. K. Indoles. US 9,114,141, issued 25 August 2015.
62. Johnson, N. W.; Kasparec, J.; Rouse, M. B.; Tian, X.; Miller, W. H.; Suarez, D. Cyclopropylamines as LSD1 inhibitors. US 9,346,840, issued 24 May 2016.
63. Knight, S. D.; Miller, W. H.; Newlander, K. A.; Donatelli, C. A. Enhancer of zeste homolog 2 inhibitors. US 9,382,234, issued 05 July 2016.
64. Brackley III, J.; Burgess, J. L.; Grant, S. W.; Johnson, N. W.; Knight, S. D.; LaFrance III, L. V.; Miller, W. H.; Newlander, K. A.; Romeril, S. P.; Rouse, M. B.; Tian, X.; Verma, S. K. Indoles. US 9,402,836, issued 02 August 2016.
65. Blackledge, Jr., C. W.; Burgess, J. L.; Johnson, N. W.; Kasparec, J.; Knight, S. D.; LaFrance III, L. V.; Luengo, J. I.; Miller, W. H.; Newlander, K. A.; Romeril, S. P.; Schulz, M.; Su, D.-S.; Tian, X. Enhancer of zeste homolog 2 inhibitors. US 9,505,745, issued 29 November 2016.
66. Miller, W. H.; Tian, X.; Verma, S. K. Indoles. US 9,649,307, issued 16 May 2017.

67. Blackledge, Jr., C. W.; Burgess, J. L.; Johnson, N. W.; Kasparec, J.; Knight, S. D.; LaFrance III, L. V.; Luengo, J. I.; Miller, W. H.; Newlander, K. A.; Romeril, S. P.; Schulz, M.; Su, D.-S.; Tian, X. Enhancer of zeste homolog 2 inhibitors. US 9,790,212, issued 17 October 2017.

68. Blum, C. A.; Caldwell, R. D.; Casaubon, R.; Disch, J. S.; Fox, R. M.; Koppetsch, K.; Miller, W. H.; Ng, P. Y.; Oalmann, C.; Perni, R. B.; Szczepankiewicz, B. G.; White, B. Substituted bridged urea analogs as sirtuin modulators. US 9,834,558, issued December 5, 2017.

69. Ellis, J. L.; Evans, K. A.; Fox, R. M.; Miller, W. H.; Seefeld, M. A. Substituted bridged urea analogs as sirtuin modulators. US 10,072,011, issued September 11, 2018.

PUBLICATIONS

1. Miller, W. H.; Ryckman, D. M.; Goekjian, P. G.; Wang, Y.; Kishi, Y. Preferred conformation of C-glycosides. 5. Experimental support for the conformational similarity between C- and O-disaccharides. J. Org. Chem. 1988, 53, 5580-5582.

2. Wang, Y.; Goekjian, P. G.; Ryckman, D. M.; Miller, W. H.; Babirad, S. A; Kishi, Y. Preferred conformation of C-glycosides. 9. Conformational analysis of 1,4-linked carbon disaccharides. J. Org. Chem. 1992, 57, 482-489.

3. Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Karash, C. B.; Keenan, R. M.; Kopple, K. D.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W. Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide. J. Am. Chem. Soc. 1993, 115, 8861-8862.

4. Kress, M. H.; Ruel, R.; Miller, W. H.; Kishi, Y. Synthetic studies toward the taxane class of natural products. Tetrahedron Lett. 1993, 34, 5999-6002.

5. Kress, M. H.; Ruel, R.; Miller, W. H.; Kishi, Y. Investigations of the intramolecular Ni(II)/Cr(II)-mediated coupling reaction: application to the taxane ring system. Tetrahedron Lett. 1993, 34, 6003-6006.

6. Miller, W. H.; Pinto, D. J. P.; McHugh, R. J., Jr.; Arner, E. C.; Pratta, M. A.; Magolda, R. L. Inhibition of cartilage degradation by isothiazoloquinolinones. Bioorg. Med. Chem. Lett. 1994, 4, 843.

7. Bondinell, W. E.; Keenan, R. M.; Miller, W. H.; Ali, F. E.; Allen, A. C.; DeBrosse, C. W.; Eggleston, D. S.; Erhard, K. F.; Haltiwanger, R. C.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Koster, P. F.; Ku, T. W.; Lee, C. P.; Nichols, A. J.; Ross, S. T.; Samanen, J. M.; Valocik, R. E.; Vasko-Moser, J. A.; Venslavsky, J. W.; Wong, A. S.; Yuan, C.-K. Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Bioorg. Med. Chem. 1994, 2, 897-908.

8. Ku, T. W.; Miller, W. H.; Bondinell, W. E.; Keenan, R. M.; Nichols, A. J.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Huffman, W. F. Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore. J. Med. Chem. 1995, 38, 9-12.

9. Miller, W. H.; Newlander, K. A.; Eggleston, D. S.; Haltiwanger, R. C. Synthesis of a 2-benzazepine analog of a potent, nonpeptide GPIIb/IIIa antagonist. Tetrahedron Lett., 1995, 36, 373-376.

10. Miller, W. H.; Ku, T. W.; Ali, F. E.; Bondinell, W. E.; Calvo, R. R.; Davis, L. D.; Erhard, K. F.; Hall, L. B.; Huffman, W. F.; Keenan, R. M.; Kwon, C.; Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Takata, D. T.; Yuan, C.-K. Enantiospecific synthesis of SB 214857, a potent, orally active, nonpeptide fibrinogen receptor antagonist. Tetrahedron Lett. 1995, 36, 9433-9436.

11. Samanen, J.; Ali, F. E.; Barton, L.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Chen, W.; Chen, L.; Erhard, K.; Heyes, R.; Hwang, S.-M.; Jakas, D.; Keenan, R.; Ku, T.; Kwon, C.; Lee, C.-P.; Miller, W.;

Newlander, K.; Nichols, A.; Peishoff, C.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Yellin, T. O.; Uzinskas, I.; Venslavsky, J.; Wong, A.; Yuan, C.-K.; Huffman, W. GPIIb/IIIa antagonists with long oral duration designed from cyclic peptides. In The Proceedings of the 14th American Peptide Symposium (Peptides: Chemistry, Structure and Biology); Kaumaya, P. T. P., Hodges, R. S., Eds.; Mayflower Scientific: Kingswinford, England, 1996, pp 679-681.

12. Miller, W. H.; Ali, F. E.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Eggleston, D. S.; Haltiwanger, R. C.; Huffman, W. F.; Hwang, S.-M.; Jakas, D. R.; Keenan, R. M.; Koster, P. F.; Ku, T. W.; Kwon, C.; Newlander, K. A.; Nichols, A. J.; Parker, M. F.; Samanen, J. M.; Southall, L. S.; Takata, D. T.; Uzinskas, I. N.; Valocik, R. E.; Vasko-Moser, J. A.; Wong, A. S.; Yellin, T. O.; Yuan, C. C. K. Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine series. Bioorg. Med. Chem. Lett. 1996, 6, 2481-2486.

13. Samanen, J. M.; Ali, F. E.; Barton, L. S.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, W.; Chen, L.; Erhard, K.; Feuerstein, G.; Heys, R.; Hwang, S. -M.; Jakas, D. R.; Keenan, R. M.; Koster, P. F.; Ku, T. W.; Kwon, C.; Lee, C. -P.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M.; Peishoff, C. E.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Vasko-Moser, J. A.; Valocik, R. E.; Yellin, T. O.; Uzinskas, I.; Venslavsky, J. W.; Wong, A.; Yuan, C. -K.; Huffman, W. F. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. J. Med. Chem. 1996, 39, 4867-4870.

14. Keenan, R. M.; Miller, W. H.; Kwon, C.; Ali, F. E.; Callahan, J. F.; Calvo, R. R.; Hwang, S. M.; Kopple, K. D.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Yuan, C. K.; Huffman, W. F. Discovery of potent nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonists. J. Med. Chem. 1997, 40, 2289-2292.

15. Keenan, R. M.; Miller, W. H.; Lago, M. A.; Ali, F. E.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Hwang, S.-M.; Jakas, D. R.; Ku, T. W.; Kwon, C.; Nguyen, T. T.; Reader, V. A.; Rieman, D. J.; Ross, S. T.; Takata, D. T.; Uzinskas, I. N.; Yuan, C. C. K.; Smith, B. R. Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 3165-3170.

16. Keenan, R. M.; Lago, M. A.; Miller, W. H.; Ali, F. E.; Cousins, R. D.; Hall, L. B.; Hwang, S.-M.; Jakas, D. R.; Kwon, C.; Louden, C.; Nguyen, T. T.; Ohlstein, E. H.; Rieman, D. J.; Ross, S. T.; Samanen, J. M.; Smith, B. R.; Stadel, J.; Takata, D. T.; Vickery, L.; Yuan, C. C. K.; Yue, T.-L. Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonist with efficacy in a restenosis model. Bioorg. Med. Chem. Lett. 1998, 8, 3171-3176.

17. Keenan, R. M.; Callahan, J. F.; Samanen, J. M.; Bondinell, W. E.; Calvo, R. R.; Chen, L.; DeBrosse, C.; Eggleston, D. S.; Haltiwanger, R. C.; Hwang, S.-M.; Jakas, D. R.; Ku, T. W.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Southall, L. S.; Uzinskas, I.; Vasko-Moser, J. A.; Venslavsky, J. W.; Wong, A. S.; Huffman, W. F. Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists. J. Med. Chem. 1999, 42, 545-559.

18. Keenan, R. M.; Miller, Barton, L. S.; W. H.; Bondinell, W. E.; Cousins, R. D.; Eppley, D. F.; Hwang, S.-M.; Kwon, C.; Lago, M. A.; Nguyen, T. T.; Smith, B. R.; Uzinskas, I. N.; Yuan, C. C. K. Nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics. Bioorg. Med. Chem. Lett. 1999, 9, 1801-1806.

19. Miller, W. H.; Bondinell, W. E.; Cousins, R. D.; Erhard, K. F.; Jakas, D. R.; Keenan, R. M.; Ku, T. W.; Newlander, K. A.; Ross, S. T.; Haltiwanger, R. C.; Bradbeer, J.; Drake, F. H.; Gowen, M.; Hoffman, S. J.; Hwang, S.-M.; James, I. E.; Lark, M. W.; Lechowska, B.; Rieman, D. J.; Stroup, G. B.; Vasko-Moser, J. A.; Zembryki, D. L.; Azzarano, L. M.; Adams, P. C.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; Huffman, W. F. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg. Med. Chem. Lett. 1999, 9, 1807-1812.

20. Lark, M. W.; Stroup, G. B.; Hwang, S.-M.; James, I. E.; Rieman, D. J.; Drake, F. H.; Bradbeer, J.; Mathur, A.; Karl F. Erhard, K. F.; Newlander, K. A.; Ross, S. T.; Salyers, K. L.; Smith, B. R.; Miller, W. H.; Huffman, W. F.; Gowen, M. Design and characterization of an orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist, SB 265123, for the prevention of bone loss in osteoporosis. J. Pharm. Exp. Ther. 1999, 291, 612-617.

21. Ward, K. W.; Azzarano, L. M.; Bondinell, W. E.; Cousins, R. D.; Huffman, W. F.; Jakas, D. R.; Keenan, R. M.; Ku, T. W.; Lundberg, D.; Miller, W. H.; Mumaw, J. A.; Newlander, K. A.; Pirhalla, J. L.; Roethke, T. J.; Salyers, K. L.; Souder, P. R.; Stelman, G. J.; Smith, B. R. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metabolism and Disposition 1999, 27, 1232-1241.

22. Miller, W. H.; Alberts, D. P.; Bhatnagar, P. K.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Erhard, K. F.; Heerding, D. A.; Keenan, R. M.; Kwon, C.; Manley, P. J.; Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Uzinskas, I. N.; Venslavsky, J. W.; Yuan, C. C. K.; Haltiwanger, R. C.; Gowen, M.; Hwang, S.-M.; James, I. E.; Lark, M. W.; Rieman, D. J.; Stroup, G. B.; Azzarano, L. M.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; Huffman, W. F. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J. Med. Chem. 2000, 43, 22-26.

23. Miller, W. H.; Keenan, R. M.; Willette, R. N.; Lark, M. W. Identification and in vivo efficacy of small molecule antagonists of integrin $\alpha v\beta 3$ (the vitronectin receptor). Drug Discovery Today, 2000, 5, 397-408.

24. Badger, A. M.; Blake, S.; Kapadia, R.; Sarkar, S.; Levin, J.; Swift, B. A.; Hoffman, S. J.; Stroup, G. B.; Miller, W. H.; Gowen, M.; Lark, M. W. Disease-modifying activity of SB 273005, an orally active, nonpeptide $\alpha v\beta 3$ (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis and Rheumatism 2001, 44, 128-137.

25. Lark, M. W.; Stroup, G. B.; Dodds, R. A.; Kapadia, R.; Hoffman, S. J.; Hwang, S. M.; James, I. E.; Lechowska, B.; Liang, X.; Rieman, D. J.; Salyers, K. L.; Ward, K.; Smith, B. R.; Miller, W. H.; Huffman, W. F.; Gowen, M. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. J. Bone Min. Res., 2001, 16, 319-327.

26. Heerding, D. A.; Chan, G.; DeWolf, W. E., Jr.; Fosberry, A. P.; Janson, C. A.; Jaworski, D. D.; McManus, E.; Miller, W. H.; Moore, T. D.; Payne, D. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Smith, W.; Takata, D. T.; Vaidya, K. S.; Yuan, C. C. K.; Huffman, W. F. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg. Med. Chem. Lett. 2001, 11, 2061-2065.

27. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; DeWolf, W. E., Jr.; Keller, P. M.; Qiu, X.; Janson, C. A.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Jaworski, D. D.; Slater-Radosti, C.; Huffman, W. F. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett., 2001, 11, 2241-2244.

28. Hoffman, S. J.; Vasko-Moser, J.; Miller, W. H.; Lark, M. W.; Gowen, M.; Stroup, G. Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist. J. Pharm. Exp. Ther. 2002, 302, 205-211.

29. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Heerding, D. A.; Yuan, C. C. K.; Head, M. S.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; Pearson, S. C.; Berry, V.; DeWolf, W. E., Jr.; Keller, P. M.; Polizzi, B. J.; Qiu, X.; Janson, C. A.; Huffman, W. F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 2002, 45, 3246-3256.

30. Payne, D. J.; Miller, W. H.; Berry, V.; Brosky, J.; Burgess, W. J.; Chen, E.; DeWolf, W. E., Jr.; Fosberry, A. P.; Greenwood, R.; Head, M. S.; Heerding, D. A.; Janson, C. A.; Jaworski, D. D.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Newlander, K. A.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Salyers, K. L.; Seefeld, M. A.; Smyth, M. G.; Takata, D. T.; Uzinskas, I. N.; Vaidya, K.; Wallis, N. G.; Winram, S. B.; Yuan, C. C. K.; Huffman, W. F. Discovery of a novel and potent class of FabI directed antibacterial agents. Antimicrob. Agents Chemother. 2002, 46, 3118-3124.

31. Fan, F.; Yan, K.; Wallis, N. G.; Reed, S.; Moore, T. D.; Rittenhouse, S. F.; DeWolf, W. E., Jr.; Huang, J.; McDevitt, D.; Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Jakas, D. R.; Head, M. S.; Payne, D. J. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 2002, 46, 3343-3347.

32. Miller, W. H.; Manley, P. J.; Cousins, R. D.; Erhard, K. F.; Heerding, D. A.; Kwon, C.; Ross, S. T.; Samanen, J. M.; Takata, D. T.; Uzinskas, I. N.; Yuan, C. C. K.; Haltiwanger, R. C.; Gress, C. J.; Lark, M. W.; Hwang, S.-M.; James, I. E.; Rieman, D. J.; Willette, R. N.; Yue, T.-L.; Azzarano, L. M.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; Huffman, W. F. Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin $\alpha v\beta 3$) antagonists. Bioorg. Med. Chem. Lett., 2003, 13, 1483-1486.

33. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; DeWolf, W. E., Jr.; Elkins, P. A.; Head, M. S.; Jakas, D. R.; Janson, C. A.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Payne, D. J.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Uzinskas, I. N.; Wallis, N. G.; Huffman, W. F. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem. 2003, 46, 1627-1635.

34. Medina, J.; Blackledge, C.; Erhard, K.; Axten, J.; Miller, W. Benzyl 2-cyano-3,3-dimethyl-1-pyrrolidinecarboxylate, a versatile intermediate for the synthesis of 3,3-dimethylproline derivatives. J. Org. Chem. 2008, 73(10), 3946-3949.

35. Rouse, M. B.; Seefeld, M. A.; Heerding, D. A.; Leber, J. D.; Miller, W. H.; Rhodes, N.; Kumar, R.; Choudhry, A. E.; Concha, N. O.; Lai, Z.; McNulty, K. C.; Minthorn, E. A.; Schaber, M. D.; Sun, L.; Warren, G. L.; Zhang, S. Y. Aminofurazans as potent inhibitors of AKT kinase. Bioorg. Med. Chem. Lett. 2009, 19(5), 1508-1511.

36. Medina, J. R.; Grant, S. W.; Axten, J. M.; Miller, W. H.; Donatelli, C. A.; Hardwicke, M. A.; Oleykowski, C. A.; Liao, Q.; Plant, R.; Xiang, H. Discovery of a new series of aurora inhibitors through truncation of GSK1070916. Bioorg. Med. Chem. Lett. 2010, 20(8), 2552-2555.

37. Medina, J. R.; Becker, C. J.; Blackledge, C. W.; Duquenne, C.; Feng, Y.; Grant, S. W.; Heerding, D.; Li, W. H.; Miller, W. H.; Romeril, S. P.; Scherzer, D.; Shu, A.; Bobko, M. A.; Chadderton, A. R.; Dumble, M.; Gardiner, C. M.; Gilbert, S.; Liu, Q.; Rabindran, S. K.; Sudakin, V.; Xiang, H.; Brady, P. G.; Campobasso, N.; Ward, P.; Axten, J. M. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. J. Med. Chem. 2011, 54(6), 1871-95.

38. Miles, T. J.; Axten, J. M.; Barfoot, C.; Brooks, G.; Brown, P.; Chen, D.; Dabbs, S.; Davies, D. T.; Downie, D. L.; Eyrisch, S.; Gallagher, T.; Giordano, I.; Gwynn, M. N.; Hennessy, A.; Hoover, J.; Huang, J.; Jones, G.; Markwell, R.; Miller, W. H.; Minthorn, E. A.; Rittenhouse, S.; Seefeld, M.; Pearson, N. Novel amino-piperidines as potent antibacterials targeting bacterial type II topoisomerases. Bioorg. Med. Chem. Lett. 2011, 21, 7489-7495.

39. Axten, J. M.; Medina, J. R.; Blackledge, C. W.; Duquenne, C.; Grant, S. W.; Bobko, M. A.; Peng, T.; Miller, W. H.; Pinckney, T.; Gallagher, T. F.; Kulkarni, S.; Lewandowski, T.; Van Aller, G. S.; Zonis, R.; Ward, P.; Campobasso, N. Acylprolinamides: A new class of peptide deformylase inhibitors with in vivo antibacterial activity. Bioorg. Med. Chem. Lett. 2012, 22(12), 4028–4032.

40. McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G. S.; Liu, Y.; Graves, A. P.; Della Pietra III, A.; Diaz, E.; LaFrance, L. V.; Mellinger, M.; Duquenne, C.; Tian, X.; Kruger, R. G.; McHugh,

C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy; C. L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492, 108-112.

41. Verma, S.; Tian, X.; LaFrance, L. V.; Duquenne, C.; Suarez, D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J.; Grant, S. W.; Brackley, J. A.; Scherzer, D. A.; Shu, A.; Graves, A. P.; Thompson, C. S.; Ott, H.; Van Aller, G. S.; Machutta, C.; Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak, D.; Tummino, P.; Creasy, C. L.; Miller, W. H. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med. Chem. Lett. 2012, 3(12), 1091–1096.

42. Van Aller, G. S.; Pappalardi, M. B.; Ott, H. M.; Diaz, E.; Brandt, M.; Schwartz, B. J.; Miller, W. H.; Dhanak, D.; McCabe, M. T.; Verma, S. K.; Creasy, C. L.; Tummino, P. J.; Kruger, R. G. Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2. ACS Chemical Biology 2014, 9(3), 622-629.

43. Mohammad, H. P.; Smitheman, K. N.; Kamat, C. D.; Soong, D.; Federowicz, K. E.; Van Aller, G. S.; Schneck, J. L.; Carson, J. D.; Liu, Y.; Butticello, M.; Bonnette, W. G.; Gorman, S. A.; Degenhardt, Y.; Bai, Y.; McCabe, M. T.; Pappalardi, M. B.; Kasparec, J.; Tian, X.; McNulty, K. C.; Rouse, M.; McDevitt, P.; Ho, T.; Crouthamel, M.; Hart, T. K.; Concha, N. O.; McHugh, C. F.; Miller, W. H.; Dhanak, D.; Tummino, P. J. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell 2015, 28(1), 57-69.

PRESENTATIONS

1. Miller, W. H.; Bondinell, W. E.; Keenan, R. M.; Ku, T. W.; Newlander, K. A.; Samanen, J. M.; Hwang, S.-M.; Wong, A. S.; Koster, P. F.; Nichols, A. J.; Valocik, R. E.; Vasko-Moser, J. A.; Eggleston, D. S.; Haltiwanger, R. C. 2-benzazepine-4-acetic acid derivatives as fibrinogen receptor antagonists. Poster presentation at the Medicinal Chemistry Gordon Conference, New London, NH, August 7-12, 1994.

2. Miller, W.; Ali, F. E.; Barton, L.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Chen, L.; Erhard, K.; Hwang, S.-M.; Jakas, D.; Keenan, R.; Ku, T.; Kwon, C.; Lee, C.-P.; Newlander, K.; Nichols, A.; Parker, M.; Peishoff, C.; Rhodes, G.; Ross, S.; Samanen, J.; Simpson, R.; Takata, D.; Yellin, T. O.; Uzinskas, I.; Venslavsky, J.; Yuan, C.-K.; Huffman, W. Orally active nonpeptide GPIIb/IIIa antagonists designed from cyclic peptides. Oral presentation at the Western Biotech Conference, San Diego, CA, October 18-21, 1995.

3. Miller, W.; Keenan, R.; Ali, F.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Cousins, R.; Gowen, M.; Huffman, W.; Hwang, S.; Jakas, D.; Ku, T.; Kwon, C.; Lago, A.; Nguyen, T.; Reader, V.; Ross, S.; Samanen, J.; Southall, L.; Takata, D.; Uzinskas, I.; Venslavsky, J.; Wong, A.; Yellin, T.; Yuan, C. Nonpeptide vitronectin receptor antagonists. Oral presentation at the Fourth Annual Development of Small Molecule Mimetic Drugs Conference, Washington, D.C., May 2-3, 1996.

4. Miller, W.; Keenan, R.; Ali, F.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Cousins, R.; Gowen, M.; Huffman, W.; Hwang, S.; Jakas, D.; Ku, T.; Kwon, C.; Lago, A.; Nguyen, T.; Reader, V.; Ross, S.; Samanen, J.; Southall, L.; Takata, D.; Uzinskas, I.; Venslavsky, J.; Wong, A.; Yellin, T.; Yuan, C. Nonpeptide vitronectin receptor antagonists. Poster presentation at the XIVth International Symposium on Medicinal Chemistry, Maastricht, the Netherlands, September 8-12, 1996.

5. Miller, W. H.; Keenan, R. M.; Ali, F. E.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Gowen, M.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; James, I. E.; Ku, T. W.; Kwon, C.; Lago, M. A.; Nguyen, T. T.; Reader, V. A.; Ross, S. T.; Samanen, J. M.; Southall, L. S.; Stadel, J. M.; Takata, D. T.; Uzinskas, I. N.; Venslavsky, J. W.; Wong, A. S.; Yuan, C.; Yue, T. L.; Zembryki, D. Nonpeptide vitronectin receptor antagonists. Oral presentation at the Lead Generation and Optimization Conference, Princeton, NJ, September 18-19, 1996.

6. Miller, W. H.; Bondinell, W. E.; Cousins, R. D.; Erhard, K. F.; Keenan, R. M. Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Bradbeer, J.; Drake, F. H.; Hoffman, S. J.; Hwang, S. M.; James, I. E.; Lark, M. W.; Lechowska, B.; Lee-Rykaczewski, E.; Stroup, G. B.; Zembryki, D. L.; Yue, T.-L.; Smith, B. R.; Gowen, M.; Huffman, W. F. The discovery of orally active nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonists. Oral presentation at the 215th ACS National Meeting, Dallas, TX, March 29-April 2, 1998.

7. Miller, W. H.; Cousins, R. D.; Erhard, K. F.; Haltiwanger, R. C.; Keenan, R. M. Newlander, K. A.; Ross, S. T.; Bradbeer, J.; Drake, F. H.; Gowen, M.; Hoffman, S. J.; Hwang, S. M.; James, I. E.; Lark, M. W.; Lechowska, B.; Lee-Rykaczewski, E.; Stroup, G. B.; Vasko-Moser, J. A.; Zembryki, D. L.; Salyers, K. L.; Smith, B. R.; Ward, K. W; Huffman, W. F. The discovery of orally active nonpeptide vitronectin receptor ($\alpha v\beta 3$) antagonists. Oral presentation at the 3rd Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 23-29, 1999.

8. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Manley, P. J.; Heerding, D. A.; Takata, D. T.; Yuan, C. C. K.; Head, M. S.; Berry, V.; Greenwood, R.; Jaworski, D. D.; Jepras, R. I.; Moore, T. D.; Payne, D. J.; Pearson, S. C.; Rittenhouse, S. F.; Slater-Radosti, C. E.; Straub, R. J.; Wallis, N. G.; DeWolf, W. E., Jr.; Keller, P. M.; Jansen, C. A.; Qiu, X.; Chen, E.; Salyers, K. L.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Huffman, W. F. Inhibitors of bacterial enoyl-ACP reductase (FabI) 1: Discovery of a novel aminopyridine-based FabI inhibitor with in vivo antibacterial activity. Oral presentation at the 222nd ACS National Meeting, Chicago, IL, August 26-30, 2001.

9. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Jakas, D. R.; Manley, P. J.; Heerding, D. A.; Takata, D. T.; Yuan, C. C. K.; Head, M. S.; Payne, D. J.; Berry, V.; Broskey, J.; Greenwood, R.; Jaworski, D. D.; Moore, T. D.; Pearson, S.; Rittenhouse, S. F.; Slater-Radosti, C..; Straub, R. J.; Van Aller, G. S.; Voelker, L. L.; Wallis, N. G.; Winram, S. B.; DeWolf, W. E., Jr.; Keller, P. M.; Polizzi, B. J.; Qiu, X.; Janson, C. A.; Chen, E.; Gorycki, P. D.; Salyers, K. L.; Bolgunas, S. P.; Cheng, H.-Y.; Geng , X. X.; Oshiro, K. K.; Jepras, R. I.; Tolson, D. A.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Huffman, W. F. Discovery and characterization of a novel aminopyridine-based FabI inhibitor with in vivo antibacterial activity. Poster presentation at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 16-19, 2001, Chicago, IL.

10. Miller, W. H. Discovery of small molecule inhibitors of the histone methyltransferase EZH2. Oral presentation at the NESACS Symposium on Epigenetic Targets, December 13, 2012, Waltham, MA.